Targets › IGHM
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Immunology; next expected readout Mar 2027.
Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. (UniProt, P01871)
Open in Phaseline: the race on IGHM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| RAPT Therapeutics, Inc., a member of the GSK plc group of companies | RPT904 anti-IgE monoclonal antibody | IGHM | Phase 2 | Immune System Diseases | Mar 2027 |
| Lycia Therapeutics | LCA-0061 Antibody-based therapeutic designed to selectively bind and rapidly clear immunoglobulin E | IGHM | Phase 1 | Atopic Disease | Apr 2028 |
Immune System Diseases (1) Atopic Disease (1)
antibody (1), small molecule (1)
RAPT Therapeutics, Inc., a member of the GSK plc group of companies (1) Lycia Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.